Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9872062 | International Journal of Radiation Oncology*Biology*Physics | 2005 | 8 Pages |
Abstract
Conclusion: After 5-fluorouracil-based CRT, a positive CRM predicted for a high risk of subsequent local recurrence and a 3-year disease-free survival rate of only 9%. For this reason, the CRM should be considered a major prognostic factor and should be validated in future trials as an early alternative clinical endpoint.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Suzannah (F.R.C.R.), Rob (F.R.C.P., F.R.C.R.), Juliet Grainger, Paul (F.R.C.Path.), Andreas (F.R.C.R.), Mark (F.R.C.R.), Richard (F.R.C.R.), Richard A. (F.R.C.S.), Melanie (F.R.C.R.), Jeremy I. (F.R.C.S.), Peter (F.R.C.S.), Ian C. (F.R.C.S.),